CMVLF (Cellectis) Cyclically Adjusted FCF per Share: $-1.59 (As of Mar. 2026)


CMVLF Cellectis SA CMVLF
59 GF Score
Price $3.47
GF Value $3.30
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cellectis Cyclically Adjusted FCF per Share?

Cellectis CMVLF 59 Cyclically Adjusted FCF per Share is $-1.59 as of Mar. 2026. GuruFocus rates CMVLF with a GF Score™ of 59/100 and a GF Value™ of $3.30 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Cellectis's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.156. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.59 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Cellectis was 3.70% per year. The lowest was 2.40% per year. And the median was 3.05% per year.

As of today (2026-07-06), Cellectis's current stock price is $3.47. Cellectis's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-1.59. Cellectis's Cyclically Adjusted Price-to-FCF of today is .


Cellectis  (OTCPK:CMVLF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Cellectis Cyclically Adjusted FCF per Share Related Terms


Cellectis Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Cellectis's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectis Cyclically Adjusted FCF per Share Chart

Cellectis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.72 -1.78 -1.77 -1.35 -1.59

Cellectis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.54 -1.41 -1.56 -1.59 -1.59

CMVLF vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Cellectis's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cellectis's Cyclically Adjusted Price-to-FCF falls into.


CMVLF
59GF Score
Cellectis SA CMVLF
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectis Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cellectis's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.156/122.4300*122.4300
=-0.156

Current CPI (Mar. 2026) = 122.4300.

Cellectis Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.363 100.630 -0.442
201609 -0.123 100.340 -0.150
201612 0.015 100.650 0.018
201703 -0.470 101.170 -0.569
201706 -0.334 101.320 -0.404
201709 -0.453 101.330 -0.547
201712 -0.279 101.850 -0.335
201803 -0.572 102.750 -0.682
201806 -0.310 103.370 -0.367
201809 -0.383 103.560 -0.453
201812 -0.544 103.470 -0.644
201903 -0.570 103.890 -0.672
201906 -0.571 104.580 -0.668
201909 -0.662 104.500 -0.776
201912 -0.130 104.980 -0.152
202003 -0.153 104.590 -0.179
202006 -0.852 104.790 -0.995
202009 -0.752 104.550 -0.881
202012 -1.175 104.960 -1.371
202103 -1.146 105.750 -1.327
202106 -0.387 106.340 -0.446
202109 -0.789 106.810 -0.904
202112 -0.451 107.850 -0.512
202203 -0.819 110.490 -0.908
202206 -0.543 112.550 -0.591
202209 -0.586 112.740 -0.636
202212 -0.032 114.160 -0.034
202303 -0.555 116.790 -0.582
202306 -0.377 117.650 -0.392
202309 -0.284 118.260 -0.294
202312 0.603 118.390 0.624
202403 -0.229 119.470 -0.235
202406 0.569 120.200 0.580
202409 -0.066 119.560 -0.068
202412 -0.018 119.950 -0.018
202503 -0.175 120.380 -0.178
202506 -0.106 121.360 -0.107
202509 -0.038 120.950 -0.038
202512 -0.108 120.900 -0.109
202603 -0.156 122.430 -0.156

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-1.59 mean?
Cellectis (CMVLF) has a Cyclically Adjusted FCF per Share of $-1.59 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Cellectis and its competitors.
Is Cellectis' Cyclically Adjusted FCF per Share too high?
Cellectis' current Cyclically Adjusted FCF per Share is $-1.59. Overall, Cellectis has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cellectis' Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Cellectis' Cyclically Adjusted FCF per Share of $-1.59 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Cellectis and its competitors. Cellectis's current Cyclically Adjusted FCF per Share is $-1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectis stock overvalued right now?
Based on GuruFocus' analysis, Cellectis (CMVLF) is currently considered Fairly Valued. The stock's GF Value™ is $3.30, compared to a current price of $3.47 — trading 5.2% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-1.59. Cellectis' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Cellectis (CMVLF), the current Cyclically Adjusted FCF per Share is $-1.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cellectis (CMVLF) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be overvalued. The current stock price of $3.47 is trading 5.2% above its estimated GF Value™ of $3.30. GuruFocus considers Cellectis to be Fairly Valued.

Key valuation signals for CMVLF:

  • Cyclically Adjusted FCF per Share: $-1.59
  • GF Value™: $3.30 vs. price of $3.47 (5.2% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the CMVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
59GF Score

Get the complete analysis for CMVLF

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.47
Price
$3.30
GF Value